{
  "docId": "019dd923-622c-750b-8b9a-3bcd52c6e583",
  "docSlug": "f06b0b5d2079",
  "documentTitle": "Soleno Therapeutics (SLNO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2025-08-15 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 332,
  "pageCount": 415,
  "prevPage": 331,
  "nextPage": 333,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a direct quote from an endocrinologist to undermine the primary endpoint of a clinical trial.",
  "elementsJson": [
    "paragraph",
    "callout_box",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-3bcd52c6e583/332",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583#slide-332",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "The other fundamental issue is actually the HQ-CT score. It's not a great marker. It's the only tool that we have as validated. But it's not perfect. You're basing a lot of your study or your analysis on something that's not perfect.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b2b2-5f0f08303185",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.86,
        "x": 0.07,
        "y": 0.42
      },
      "kind": "paragraph",
      "text": "HQ-CT score is unreliable and subjective; baseline scores were unusually high and unclear if a \"true genuine score\"; questioning whether the decline from an inflated score is due to placebo effect",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ce66e989-6850-4354-9bb7-31d9b2972420",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.86,
        "x": 0.07,
        "y": 0.48
      },
      "kind": "quote",
      "text": "The other fundamental issue is actually the HQ-CT score. It's not a great marker. It's the only tool that we have as validated. But it's not perfect. You're basing a lot of your study or your analysis on something that's not perfect. It's not like your HbA1c or your cholesterol level. It's a subjective score. It's not a hard and fast measurement..it will vary depending on who's done it, whether it's the mom, the dad, or grandparents. In terms of the median score of 20, that's a very high score. And most of my patients are nowhere near that. Now, whether that's a true genuine score or not, I don't know...If they've got such a high score, is it just purely a placebo effect goes down for the score from 23 down to 15, is that really the drug? Is that placebo? Is that the fact that they've done a trial? I don't know.\"",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a8449155-8a1c-4db2-87fe-9a3b8cf130a1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "the HQ-CT score, it’s not a great marker...it’s a subjective core...will vary depending on...whether it’s the mom, dad, or grandparents; the median score of 20, that’s a very high score...most of my patients are nowhere near that...is it just placebo effect goes down for the score from 23 down to 15...is that really the drug? — Trial investigator, endocrinologist, key opinion leader for PWS",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b2b2-607325169b82",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.07,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Scorpion Capital consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c6f99220-2cdd-4bbc-b7cf-71b25f576ae2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.32,
        "w": 0.86,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "title",
      "text": "Trial investigator #7 was highly critical of the HQ-CT endpoint, blasting it as a soft, subjective endpoint unlike histologic markers.",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8076d334-e175-47e9-b465-4162cec35fa5",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "antagonist-introduction",
      "slug": null,
      "matchId": "fe4d3324-ba2e-4f21-ad63-dd021a0f61a4",
      "evidence": "Uses an expert witness to frame the company's primary endpoint as a 'soft' and unreliable metric.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}